Richter, Hikma Sign Commercialisation and Licence Agreement for Denosumab in US

Global

Hungarian pharmaceutical company Gedeon Richter said it entered into an exclusive licence agreement with UK-headquartered Hikma Pharmaceuticals to commercialise its drug denosumab, used to treat osteoporosis and fractures due to bone metastasis, in the United States.

 

Denosumab comprises two biosimilar products referencing the brands Prolia and Xgeva. Under the agreement, Richter is responsible for the development of the products, conducting both Phase 1 and Phase 3 global clinical studies, and will supply the products for the US market. Hikma will be responsible for registering the products with the US Food and Drug Administration (FDA) and will have exclusive rights to commercialise them in the United States. Richter is eligible for an upfront payment and milestone payments totalling “a double-digit million USD figure” under the financial terms of the agreement.

 

hungarymatters.hu

pixabay

Iris Properties

- Brand new flat next to Uni

54 m2 flat for rent
400 000 Ft

- Sunny flat close to Fórum

95 m2 flat for rent
420 000 Ft

- Petfriendly flat next to Pálma

65 m2 flat for rent
220 000 Ft

- Homy flat in the Center

44 m2 flat for rent
230 000 Ft

Leave a Reply

Your email address will not be published. Required fields are marked *